|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0770 EUR | -3.02% |
|
+9.07% | +18.10% |
| Mar. 09 | TME Pharma N.V. Extends Maturity of EUR 2.06 Million Loans and Announces Early Redemption of EUR 163,562.50 Bonds | CI |
| Mar. 09 | TME Pharma Secures 12-month Loan Extension | MT |
Company Valuation: TME Pharma N.V.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 7.587 | 24.37 | 17.44 | 1.653 | 1.22 | 7.059 |
| Change | - | 221.14% | -28.42% | -90.52% | -26.24% | 478.85% |
| Enterprise Value (EV) 1 | 6.331 | 14.17 | 10.42 | 1.105 | 0.1405 | 3.819 |
| Change | - | 123.79% | -26.43% | -89.4% | -87.29% | 2,618.09% |
| P/E ratio | -7.28x | -1.75x | -1.07x | -0.09x | -0.17x | -0.47x |
| PBR | -4.12x | 3.43x | 3.86x | -1.65x | -13.5x | 4.37x |
| PEG | - | -0x | 0x | 0x | 0x | 0x |
| Capitalization / Revenue | 49.3x | 696x | 528x | - | - | - |
| EV / Revenue | 41.1x | 405x | 316x | - | - | - |
| EV / EBITDA | -1.57x | -2.44x | -0.78x | -0.09x | -0.03x | -0.73x |
| EV / EBIT | -1.56x | -2.43x | -0.77x | -0.09x | -0.02x | -0.73x |
| EV / FCF | -1.06x | -3.46x | -1.42x | -0.15x | -0.04x | -1.4x |
| FCF Yield | -94.7% | -28.9% | -70.6% | -665% | -2,543% | -71.5% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -8 | -32.16 | -21.9 | -12.86 | -1.342 | -0.159 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 0.154 | 0.035 | 0.033 | - | - | - |
| EBITDA 1 | -4.044 | -5.807 | -13.44 | -11.99 | -5.593 | -5.241 |
| EBIT 1 | -4.064 | -5.824 | -13.46 | -12.01 | -5.624 | -5.258 |
| Net income 1 | -0.861 | -10.4 | -14.45 | -15.13 | -6.736 | -5.722 |
| Net Debt 1 | -1.256 | -10.2 | -7.016 | -0.548 | -1.079 | -3.24 |
| Reference price 2 | 58.2000 | 56.2000 | 23.4000 | 1.2158 | 0.2300 | 0.0750 |
| Nbr of stocks (in thousands) | 130 | 434 | 745 | 1,360 | 5,302 | 94,122 |
| Announcement Date | 4/22/20 | 4/28/21 | 4/22/22 | 4/24/23 | 4/25/24 | 4/25/25 |
1EUR in Million2EUR
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 8.29M | |
| 33.07x | 4.92x | 16.5x | 1.02% | 42.78B | |
| 51.27x | 4.42x | 29.75x | -.--% | 31.5B | |
| 54.26x | 11.14x | 30.96x | 0.35% | 29.99B | |
| 19.97x | 2.36x | 10.18x | -.--% | 27.65B | |
| -12.38x | 320.84x | -10.44x | -.--% | 18.8B | |
| 43.12x | 8.22x | 25.82x | -.--% | 13.87B | |
| 26.34x | 4.19x | 19.06x | -.--% | 12.78B | |
| 20.1x | 1.87x | 8.16x | 1.23% | 12.39B | |
| -17.61x | 13.71x | -19.11x | -.--% | 11.76B | |
| Average | 24.24x | 41.30x | 12.32x | 0.29% | 20.15B | |
| Weighted average by Cap. | 29.54x | 35.39x | 15.55x | 0.34% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- ALTME Stock
- Valuation TME Pharma N.V.
Select your edition
All financial news and data tailored to specific country editions
